United States Migraine Nasal Spray Market 2031 | Growth Drivers, Trends & Market Forecast, Competitive Landscape & Investment Opportunities

Market Size and Growth

Migraine Nasal Spray Market is forecast to reach at a high CAGR during the forecast period (2024-2031)

Get a Free Sample PDF Of This Report (Get Higher Priority for Corporate Email ID):- https://www.datamintelligence.com/download-sample/migraine-nasal-spray-market?sb

Key Development:

United States: Recent Migraine Nasal Spray & Related Developments

✅ In November 2025, Satsuma Pharmaceuticals received U.S. FDA approval for AtzumiTM (dihydroergotamine nasal powder) for the acute treatment of migraine with or without aura in adults, marking a new easy‐to‐use intranasal acute option using proprietary SMART delivery technology.

✅ In November 2025, ARS Pharmaceuticals reported strong growth for neffy® epinephrine nasal spray, indicating expanding direct‐to‐consumer adoption and reinforcing focus on self‐administered nasal therapies.

✅ In April 2025, the U.S. FDA approved AtzumiTM (formerly STS101) after earlier manufacturing setbacks, renewing the acute migraine nasal option based on rapid absorption and sustained DHE levels.

✅ In March 2025, the FDA expanded indications for neffy® nasal spray to include younger pediatric patients aged 4 and older weighing 15-30 kg, showing broader nasal delivery approvals across indications.

Buy Now & Unlock 360° Market Intelligence: https://www.datamintelligence.com/buy-now-page?report=migraine-nasal-spray-market

Japan: Recent Related Nasal Spray & Regulatory Movements

✅ In November 2025, Japan's Central Social Insurance Medical Council approved reimbursement listing of several new drugs, highlighting an evolving regulatory environment favoring advanced therapies.

✅ In September 2025, Japan's PMDA approved neffy® nasal spray (epinephrine) in both 1 mg and 2 mg doses as the first needle‐free emergency treatment for anaphylaxis, reflecting expanded nasal delivery acceptance in Japan.

✅ In July 2025, the Japan Patent Office allowed Altamira Therapeutics' patent application covering intranasal betahistine formulations, which could support future nasal drug innovation including pain/neurological symptom modulation.

✅ In late 2025, industry reports noted enhanced R&D and clinical interest in migraine nasal sprays and advanced delivery systems in Japan, suggesting regional innovation momentum continues.

Key Players:

=> Pfizer Inc., Impel Pharmaceuticals Inc., Upsher-Smith Laboratories, LLC., Lannett Company, GlaxoSmithKline plc, SteriMax Inc., Assertio Therapeutics, Inc., Cipla Inc., AstraZeneca Plc. and Dr. Reddy's Laboratories Ltd. among others.

Speak to Our Analyst and Get Customization in the report as per your requirements: https://www.datamintelligence.com/customize/migraine-nasal-spray-market?sb

Key Segments:

By Chemical Type

Triptan Nasal Sprays lead with 40% share, widely used for acute migraine relief due to fast onset of action.
Dihydroergotamine Nasal Sprays hold 25%, primarily prescribed for severe or complicated migraine cases.
Nasal K€torolac accounts for 20%, gaining traction as a non-opioid anti-inflammatory option.
Others represent 15%, including emerging and niche formulations for migraine management.

By Dosage

5 mg - 30% share, commonly prescribed for mild migraine attacks.
10 mg - 40% share, preferred for standard acute treatment.
20 mg - 20% share, used in severe or resistant migraine cases.
Others - 10% share, including customized or combination formulations.

By Application

Complicated Migraine - 25% share, including patients with aura or neurological symptoms.
Common Migraine - 30% share, representing the majority of migraine sufferers.
Chronic Migraine - 20% share, reflecting growing awareness and diagnosis.
Ocular Migraine - 15% share, a niche segment with specific therapeutic needs.
Others - 10% share, including atypical or drug-resistant migraine types.

By Distribution Channel

Hospital Pharmacies - 35% share, preferred for prescription-based and acute treatments.
Retail Pharmacies - 40% share, convenient for recurring or self-managed treatments.
Online Pharmacies - 25% share, growing due to telemedicine adoption and e-commerce convenience.

By Region

North America - 35% Share
High awareness, established migraine treatment protocols, and well-developed pharmaceutical infrastructure.

Europe - 30% Share
Strong adoption of triptan and ergotamine therapies; focus on chronic migraine management.

Asia Pacific - 20% Share
Rapid market growth driven by rising migraine prevalence and expanding healthcare access.

Latin America - 10% Share
Emerging market; growth from urban healthcare infrastructure and increasing patient awareness.

Middle East & Africa - 5% Share
Small but growing market, primarily in urban centers with improved healthcare facilities.

Unlock 360° Market Intelligence with DataM Subscription Services: https://www.datamintelligence.com/reports-subscription?sb

Power your decisions with real-time competitor tracking, strategic forecasts, and global investment insights all in one place.

✅ Competitive Landscape
✅ Sustainability Impact Analysis
✅ KOL / Stakeholder Insights
✅ Unmet Needs & Positioning, Pricing & Market Access Snapshots
✅ Market Volatility & Emerging Risks Analysis
✅ Quarterly Industry Report Updated
✅ Live Market & Pricing Trends
✅ Import-Export Data Monitoring

Have a look at our Subscription Dashboard: https://www.youtube.com/watch?v=x5oEiqEqTWg?sb

Contact Us -

Company Name: DataM Intelligence
Contact Person: Sai Kiran
Email: Sai.k@datamintelligence.com
Phone: +1 877 441 4866
Website: https://www.datamintelligence.com

About Us -

DataM Intelligence is a Market Research and Consulting firm that provides end-to-end business solutions to organizations from Research to Consulting. We, at DataM Intelligence, leverage our top trademark trends, insights and developments to emancipate swift and astute solutions to clients like you. We encompass a multitude of syndicate reports and customized reports with a robust methodology.

Our research database features countless statistics and in-depth analyses across a wide range of 6300+ reports in 40+ domains creating business solutions for more than 200+ companies across 50+ countries; catering to the key business research needs that influence the growth trajectory of our vast clientele.

This release was published on openPR.